title: Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices.
abstract: Synthetic cannabinoids (SC), originally developed as research tools, are now highly abused novel psychoactive substances. We present a comprehensive systematic review covering in vivo and in vitro animal and human pharmacokinetics and analytical methods for identifying SC and their metabolites in biological matrices. Of two main phases of SC research, the first investigated therapeutic applications, and the second abuse-related issues. Administration studies showed high lipophilicity and distribution into brain and fat tissue. Metabolite profiling studies, mostly with human liver microsomes and human hepatocytes, structurally elucidated metabolites and identified suitable SC markers. In general, SC underwent hydroxylation at various molecular sites, defluorination of fluorinated analogs and phase II metabolites were almost exclusively glucuronides. Analytical methods are critical for documenting intake, with different strategies applied to adequately address the continuous emergence of new compounds. Immunoassays have different cross-reactivities for different SC classes, but cannot keep pace with changing analyte targets. Gas chromatography and liquid chromatography mass spectrometry assays - first for a few, then numerous analytes - are available but constrained by reference standard availability, and must be continuously updated and revalidated. In blood and oral fluid, parent compounds are frequently present, albeit in low concentrations; for urinary detection, metabolites must be identified and interpretation is complex due to shared metabolic pathways. A new approach is non-targeted HRMS screening that is more flexible and permits retrospective data analysis. We suggest that streamlined assessment of new SC's pharmacokinetics and advanced HRMS screening provide a promising strategy to maintain relevant assays.
authors: Department of Chemistry and Drug Metabolism, National Institute on Drug Abuse, NIH , Baltimore, MD , USA .
authors: Marisol S
authors: MS
authors: Castaneto
authors: Ariane
authors: A
authors: Wohlfarth
authors: Nathalie A
authors: NA
authors: Desrosiers
authors: Rebecca L
authors: RL
authors: Hartman
authors: David A
authors: DA
authors: Gorelick
authors: Marilyn A
authors: MA
authors: Huestis
mesh_terms: D000818:Animals; D001711:Biotransformation; D001921:Brain / Q000378:metabolism; D002186:Cannabinoids / Q000032:analysis* / Q000737:chemistry / Q000493:pharmacokinetics*; D002853:Chromatography, Liquid / Q000379:methods; D006801:Humans; D013287:Illicit Drugs / Q000032:analysis* / Q000737:chemistry / Q000493:pharmacokinetics*; D008099:Liver / Q000378:metabolism; D013058:Mass Spectrometry / Q000379:methods; D015394:Molecular Structure; D009928:Organ Specificity; D015813:Substance Abuse Detection / Q000295:instrumentation / Q000379:methods*; D053719:Tandem Mass Spectrometry / Q000379:methods; D014018:Tissue Distribution
chemical_list: D002186:Cannabinoids; D013287:Illicit Drugs
keywords: Analysis; GC-MS; LC-MS/MS; metabolite profiling; methods; novel psychoactive substances; pharmacokinetics; review; synthetic cannabinoids